Avacta presents AVA6103 pancreatic cancer data at AACR conference
AI Summary- Avacta presented FOCUS-01 trial design and AVA6103 preclinical findings at the AACR conference.
- AVA6103 was tolerated through three dose levels, reaching approximately 50% above conventional exatecan’s MTD.
- FOCUS-01 enrollment continues in both arms, with an initial efficacy readout planned for H1 2027.